{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T23:25:02Z","timestamp":1768778702740,"version":"3.49.0"},"reference-count":33,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2024,5,27]],"date-time":"2024-05-27T00:00:00Z","timestamp":1716768000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010877","name":"Science, Technology and Innovation Commission of Shenzhen Municipality","doi-asserted-by":"publisher","award":["JCYJ20200109114244249"],"award-info":[{"award-number":["JCYJ20200109114244249"]}],"id":[{"id":"10.13039\/501100010877","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Laryngoscope Investig Oto"],"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objectives<\/jats:title><jats:p>EGFR\u2010tyrosine kinase inhibitor (TKI) is used to treat recurrent and metastatic nasopharyngeal carcinoma (rmNPC). This meta\u2010analysis aims to study the efficacy and safety of EGFR\u2010TKI in treating patients with rmNPC.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We conducted a systematic search of PubMed, Embase, and Web of Science up to November 2023, and included literature that met the criteria. We extracted objective response rate (ORR), disease control rate (DCR), median progression\u2010free survival (mPFS), median overall survival (mOS), and adverse reaction\u2010related events and performed meta\u2010analysis using Stata 14.0.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of nine articles were included. The summary results showed that the ORR for patients treated with EGFR\u2010TKI for rmNPC was 38% (95% CI\u2009=\u200927%\u201349%), the DCR was 71% (95% CI\u2009=\u200961%\u201380%), the mPFS was 6.29\u2009months (95% CI\u2009=\u20095.22\u20137.35), and the mOS was 15.94\u2009months (95% CI\u2009=\u200914.68\u201317.20). The most common grade 3\u20134 adverse reaction events in these patients were mucositis, nasopharyngeal necrosis, and oral ulceration. We found an incidence rate of 49% (95% CI\u2009=\u200938%\u201361%) for grade 3\u20134 adverse events (AEs). The anti\u2010PD1 combined with TKI treatment method is more effective than the EGFR\u2010TKI alone for treating rmNPC.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The study shows that EGFR\u2010TKI has good efficacy in treating rmNPC but does not translate into survival benefits and owns a high incidence of grade 3\u20134 AEs. More RCT trials are needed in the future to verify the efficacy of anti\u2010PD1 combined with TKI treatment method.<\/jats:p><\/jats:sec>","DOI":"10.1002\/lio2.1279","type":"journal-article","created":{"date-parts":[[2024,5,27]],"date-time":"2024-05-27T12:00:05Z","timestamp":1716811205000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The efficacy and safety of <scp>EGFR\u2010TKI<\/scp> in recurrent\/metastatic nasopharyngeal carcinoma patients: A systematic review and <scp>meta\u2010analysis<\/scp>"],"prefix":"10.1002","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-5805-2320","authenticated-orcid":false,"given":"Zeqi","family":"An","sequence":"first","affiliation":[{"name":"Department of Otorhinolaryngology Head and Neck Surgery Shenzhen University General Hospital  Shenzhen China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Libin","family":"He","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology Head and Neck Surgery Shenzhen University General Hospital  Shenzhen China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tuo","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology Head and Neck Surgery Shenzhen University General Hospital  Shenzhen China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bosen","family":"Liang","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology Head and Neck Surgery Shenzhen University General Hospital  Shenzhen China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4093-2334","authenticated-orcid":false,"given":"Qiang","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology Head and Neck Surgery Shenzhen University General Hospital  Shenzhen China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2024,5,27]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)30956-0"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31388-5"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.32099"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1079515"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2020.110649"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.2174\/1568026620666200303123102"},{"key":"e_1_2_8_8_1","first-page":"2595","article-title":"Coexpression of hypoxia\u2010inducible factors 1\u03b1 and 2\u03b1, carbonic anhydrase IX, and vascular endothelial growth factor in nasopharyngeal carcinoma and relationship to survival","volume":"8","author":"Hui EP","year":"2002","journal-title":"Clin Cancer Res"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.6268"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-20272-x"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4919"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d4002"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-020-00925-2"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01450"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-023-02790-1"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.33626"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-1667"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102043"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-40402-x"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S244102"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-023-03140-x"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6603813"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-019-0974-6"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.48.8585"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2019-0299"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-10-0111"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2016.4786"},{"key":"e_1_2_8_28_1","first-page":"249","article-title":"Nuclear EGFR is required for cisplatin resistance and DNA repair","volume":"1","author":"Hsu SC","year":"2009","journal-title":"Am J Transl Res"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202201628RR"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2023.5545"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/5479491"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1215397109"},{"key":"e_1_2_8_33_1","first-page":"2514","article-title":"Combined VEGFR and CTLA\u20104 blockade increases the antigen\u2010presenting function of intratumoral DCs and reduces the suppressive capacity of intratumoral MDSCs","volume":"6","author":"Du Four S","year":"2016","journal-title":"Am J Cancer Res"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.5732\/cjc.010.10010"}],"container-title":["Laryngoscope Investigative Otolaryngology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/lio2.1279","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T10:41:12Z","timestamp":1719225672000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/lio2.1279"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,27]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["10.1002\/lio2.1279"],"URL":"https:\/\/doi.org\/10.1002\/lio2.1279","archive":["Portico"],"relation":{},"ISSN":["2378-8038","2378-8038"],"issn-type":[{"value":"2378-8038","type":"print"},{"value":"2378-8038","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,27]]},"assertion":[{"value":"2024-02-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-09","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-27","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e1279"}}